DUBLIN--(BUSINESS WIRE)--The "Adenoid
Cystic Carcinoma Pipeline Analysis 2018 - Focusing on Clinical Trials
and Results, Drug Profiling, Patents, Collaborations, and Other Recent
Developments" report has been added to ResearchAndMarkets.com's
offering.
Adenoid Cystic Carcinoma Pipeline Analysis 2018 -
Focusing on Clinical Trials and Results, Drug Profiling, Patents,
Collaborations, and Other Developments.
Adenoid Cystic
Carcinoma Pipeline Analysis report covers more than 10 drugs currently
in different phases of development. Adenoid cystic carcinoma (ACC) is a
rare form of adenocarcinoma which occurs in the secretory glands, most
common ones include the major and minor salivary glands of neck and
head. It can occur in other locations of the body as well. This is due
to the reason that the carcinoma travels through nerves and may lead to
pain or nerve paralysis. The exact cause of ACC is however unknown and
is not caused by the inheritance. Treatment includes chemotherapy,
radiation or surgery depending on the condition of the patient.
The
report provides Adenoid Cystic Carcinoma treatment drugs by company,
phases of development including products in early discovery stage and
NDA filing, molecule type, route of administration and region. The
report will help to evaluate the collaboration, in-licensing and
out-licensing opportunities, formulating business development strategies
and tracking the activities of the key market players.
Epidemiology,
major drivers, restraints, and opportunities have been covered to
provide an exhaustive picture of the market. The analysis presents
in-depth information regarding the development, trends, and industry
policies and regulations implemented to offer stakeholders a better
understanding of the key factors affecting the overall market
environment.
Major industry players profiled as part of the
report are Merck Sharp & Dohme Corp., Lilly USA, LLC, Celgene
Corporation and Eisai Inc. among others.
Key Topics
Covered:
1. Introduction
2. Disease
Overview
3. Executive Summary
4. Market Dynamics
5.
Pipeline Analysis/Outlook
6. Company Profiling
- Merck Sharp & Dohme Corp.
- Eisai Inc.
- Bayer AG
- Celgene Corporation
- CureVac AG
- CELLESTIA BIOTECH SA
- Boston Biomedical
- OncoMed Pharmaceuticals, Inc.
- Lilly USA, LLC
- Sumitomo Dainippon Pharma Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/7wkb37/adenoid_cystic?w=4